Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$53.10 USD

53.10
4,522,270

+1.90 (3.71%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $53.09 -0.01 (-0.02%) 7:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Pepsico, Disney, Sanofi, Diageo and HCA

The Zacks Analyst Blog Highlights: Pepsico, Disney, Sanofi, Diageo and HCA

Top Ranked Income Stocks to Buy for February 6th

Here are three stocks with buy rank and strong income characteristics for investors to consider today, February 6th:

Can Sanofi (SNY) Keep the Earnings Surprise Streak Alive?

Sanofi (SNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sanofi's Myeloma Candidate Meets Goal in Phase III Study

Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.

Mark Vickery headshot

Top Research Reports for Pepsico, Walt Disney & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including Pepsico (PEP), Walt Disney Company (DIS) and Sanofi (SNY).

Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?

Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.

Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status

Merck's (MRK) investigational pneumococcal vaccine V114 gets FDA's Breakthrough Therapy designation for prevention of invasive pneumococcal disease.

Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV

J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.

Top Ranked Income Stocks to Buy for January 25th

Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 25th:

Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids

Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.

Top Ranked Income Stocks to Buy for January 23rd

Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 23rd:

Alnylam & Medison Partner to Market RNAi Products in Israel

Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.

Merck's Partner Gets FDA Nod for Herceptin Biosimilar

Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.

Top Ranked Income Stocks to Buy for January 21st

Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 21st:

Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

Top Ranked Income Stocks to Buy for January 18th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 18th

Regeneron (REGN) Sails Steady on Label Expansion of Drugs

Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.

Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

Regeneron, Sanofi Restructure Immuno-Oncology Collaboration

Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.

Emergent (EBS) Files Application for Emergency Use of NuThrax

Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.

Sanofi Wins FDA Nod for Pediatric Hexavalent Combo Vaccine

Sanofi (SNY) gains an FDA approval for its pediatric hexavalent combination vaccine, Vaxelis.

The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy

The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy

Kalyan Nandy headshot

Top Analyst Reports: Apple, Microsoft, Mastercard & More

Today's Research Daily features updated research reports on 16 major stocks including Apple Inc. (AAPL), Microsoft Corporation (MSFT) and Mastercard Inc. (MA).

Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus

Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.

Kinjel Shah headshot

5 Top Drug/Biotech Merger & Acquisition Targets for 2019

Here are five stocks that are attractive and most likely to be takeout targets in 2019.